Sage Therapeutics pill improves postpartum depression in pivotal clinical trial

Sage Therapeutics pill improves postpartum depression in pivotal clinical trial

Source: 
Stat
snippet: 

Sage Therapeutics is expecting to win its first U.S. drug approval in March for an intravenous infusion to treat women with postpartum depression. On Monday, the biotech announced arguably better news: The next drug in Sage’s pipeline — a more convenient, once-daily pill — achieved its main antidepressive goals in a pivotal Phase 3 clinical trial of women suffering from the same disease.